(Q39132688)

English

An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity

scientific article published on 7 August 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

0 references

vector-borne disease

0 references

1 reference

based on heuristic

inferred from title

3

object named as

Navin Khanna

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Sathyamangalam Swaminathan

4

object named as

Sathyamangalam Swaminathan

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

author name string

Saima Khanam

1

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Rajendra Pilankatta

2

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

language of work or name

0 references

publication date

7 August 2009

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

27

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

43

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

6011-6021

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Dengue: recent advances in biology and current status of translational research

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Dengue fever: new paradigms for a changing epidemiology

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Dengue virus: molecular basis of cell entry and pathogenesis, 25-27 June 2003, Vienna, Austria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

The future of dengue vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Review on flavivirus vaccine development. Proceedings of a meeting jointly organised by the World Health Organization and the Thai Ministry of Public Health, 26-27 April 2004, Bangkok, Thailand

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Vaccines against dengue: a review of current candidate vaccines at advanced development stages

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Towards a dengue vaccine: progress to date and remaining challenges

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Construction and Characterization of a Single-Cycle Chimeric Flavivirus Vaccine Candidate That Protects Mice against Lethal Challenge with Dengue Virus Type 2

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Evaluation of the protective efficacy of a recombinant dengue envelope B domain fusion protein against dengue 2 virus infection in mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Purified dengue 2 virus envelope glycoprotein aggregates produced by baculovirus are immunogenic in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

A DNA vaccine expressing dengue type 2 virus premembrane and envelope genes induces neutralizing antibody and memory B cells in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Immunization of rhesus monkeys with a recombinant of modified vaccinia virus Ankara expressing a truncated envelope glycoprotein of dengue type 2 virus induced resistance to dengue type 2 virus challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Short report: Antibody responses of mice immunized with a tetravalent dengue recombinant protein subunit vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Carboxy-terminally truncated Dengue 4 virus envelope glycoprotein expressed in Pichia pastoris induced neutralizing antibodies and resistance to Dengue 4 virus challenge in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

A fragment of the envelope protein from dengue-1 virus, fused in two different sites of the meningococcal P64k protein carrier, induces a functional immune response in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

A dengue-2 Envelope fragment inserted within the structure of the P64k meningococcal protein carrier enables a functional immune response against the virus in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Induction of protective antibodies against dengue virus by tetravalent DNA immunization of mice with domain III of the envelope protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Tetravalent neutralizing antibody response against four dengue serotypes by a single chimeric dengue envelope antigen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Dengue tetravalent DNA vaccine inducing neutralizing antibody and anamnestic responses to four serotypes in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Replication-Defective Adenoviral Vaccine Vector for the Induction of Immune Responses to Dengue Virus Type 2

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Two Complex, Adenovirus-Based Vaccines That Together Induce Immune Responses to All Four Dengue Virus Serotypes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

A Tetravalent Dengue Vaccine Based on a Complex Adenovirus Vector Provides Significant Protection in Rhesus Monkeys against All Four Serotypes of Dengue Virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Induction of neutralizing antibodies and T cell responses by dengue virus type 2 envelope domain III encoded by plasmid and adenoviral vectors.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

An adenovirus prime/plasmid boost strategy for induction of equipotent immune responses to two dengue virus serotypes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Pediatric Measles Vaccine Expressing a Dengue Antigen Induces Durable Serotype-specific Neutralizing Antibodies to Dengue Virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Induction of tetravalent protective immunity against four dengue serotypes by the tandem domain III of the envelope protein.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

An envelope domain III-based chimeric antigen produced in Pichia pastoris elicits neutralizing antibodies against all four dengue virus serotypes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

A ligand-binding pocket in the dengue virus envelope glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Variable surface epitopes in the crystal structure of dengue virus type 3 envelope glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Monoclonal Antibodies That Bind to Domain III of Dengue Virus E Glycoprotein Are the Most Efficient Blockers of Virus Adsorption to Vero Cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

An external loop region of domain III of dengue virus type 2 envelope protein is involved in serotype-specific binding to mosquito but not mammalian cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Structure of dengue virus: implications for flavivirus organization, maturation, and fusion

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

High-level expression and one-step purification of recombinant dengue virus type 2 envelope domain III protein in Escherichia coli

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

The envelope glycoprotein domain III of dengue virus serotypes 1 and 2 inhibit virus entry

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Type- and Subcomplex-Specific Neutralizing Antibodies against Domain III of Dengue Virus Type 2 Envelope Protein Recognize Adjacent Epitopes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Use of recombinant fusion proteins and monoclonal antibodies to define linear and discontinuous antigenic sites on the dengue virus envelope glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Characterization of Dengue Virus Complex-Specific Neutralizing Epitopes on Envelope Protein Domain III of Dengue 2 Virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Localization of a neutralizing epitope on the envelope protein of dengue virus type 2.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Mutational analysis of a neutralization epitope on the dengue type 2 virus (DEN2) envelope protein: monoclonal antibody resistant DEN2/DEN4 chimeras exhibit reduced mouse neurovirulence

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Amino acid and phenotypic changes in dengue 2 virus associated with escape from neutralisation by IgM antibody

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Identification of epitopes on the envelope (E) protein of dengue 2 and dengue 3 viruses using monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

A novel dengue vaccine candidate that induces cross-neutralizing antibodies and memory immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Adenovirus-vectored vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

A simplified system for generating recombinant adenoviruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Mapping of a region of dengue virus type-2 glycoprotein required for binding by a neutralizing monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Ectopic expression of the coxsackievirus and adenovirus receptor increases susceptibility to adenoviral infection in the human cervical cancer cell line, SiHa

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Functional and selective targeting of adenovirus to high-affinity Fcgamma receptor I-positive cells by using a bispecific hybrid adapter

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Efficient adenoviral infection with IkappaB alpha reveals that macrophage tumor necrosis factor alpha production in rheumatoid arthritis is NF-kappaB dependent

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Scientific consultation on immunological correlates of protection induced by dengue vaccines report from a meeting held at the World Health Organization 17-18 November 2005.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Neutralized adenovirus-immune complexes can mediate effective gene transfer via an Fc receptor-dependent infection pathway

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Activation of a dendritic cell-T cell axis by Ad5 immune complexes creates an improved environment for replication of HIV in T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.073

7 January 2021

Identifiers

10.1016/J.VACCINE.2009.07.073

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

release_mhjnca5amfglxaxxl4t3m37shu

1 reference

https://api.fatcat.wiki/v0/release/mhjnca5amfglxaxxl4t3m37shu

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39132688&oldid=1949456755"